NIH is thrilled to announce that the @US_FDA has granted full market approval for Papzimeos, a groundbreaking immunotherapy for adult patients with recurrent respiratory papillomatosis (RRP), a rare condition in which noncancerous growths develop in the air passages from the nose and mouth into the lungs.🫁 This is the first-ever non-surgical treatment for this rare and debilitating disease. The achievement was made possible through the dedicated research of NIH investigators from @theNCI! 🔗 Read more about the approval: fda.gov/news-events/press-an…